FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387296976> ?p ?o ?g. }

• W4387296976 abstract "Importance Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist used for the treatment of type 2 diabetes. Efficacy and safety of adding tirzepatide vs prandial insulin to treatment in patients with inadequate glycemic control with basal insulin have not been described. Objective To assess the efficacy and safety of tirzepatide vs insulin lispro as an adjunctive therapy to insulin glargine. Design, Setting, and Participants This open-label, phase 3b clinical trial was conducted at 135 sites in 15 countries (participants enrolled from October 19, 2020, to November 1, 2022) in 1428 adults with type 2 diabetes taking basal insulin. Interventions Participants were randomized (in a 1:1:1:3 ratio) to receive once-weekly subcutaneous injections of tirzepatide (5 mg [n = 243], 10 mg [n = 238], or 15 mg [n = 236]) or prandial thrice-daily insulin lispro (n = 708). Main Outcomes and Measures Outcomes included noninferiority of tirzepatide (pooled cohort) vs insulin lispro, both in addition to insulin glargine, in HbA 1c change from baseline at week 52 (noninferiority margin, 0.3%). Key secondary end points included change in body weight and percentage of participants achieving hemoglobin A 1c (HbA 1c ) target of less than 7.0%. Results Among 1428 randomized participants (824 [57.7%] women; mean [SD] age, 58.8 [9.7] years; mean [SD] HbA 1c , 8.8% [1.0%]), 1304 (91.3%) completed the trial. At week 52, estimated mean change from baseline in HbA 1c with tirzepatide (pooled cohort) was −2.1% vs −1.1% with insulin lispro, resulting in mean HbA 1c levels of 6.7% vs 7.7% (estimated treatment difference, −0.98% [95% CI, −1.17% to −0.79%]; P &amp;lt; .001); results met noninferiority criteria and statistical superiority was achieved. Estimated mean change from baseline in body weight was −9.0 kg with tirzepatide and 3.2 kg with insulin lispro (estimated treatment difference, −12.2 kg [95% CI, −13.4 to −10.9]). The percentage of participants reaching HbA 1c less than 7.0% was 68% (483 of 716) with tirzepatide and 36% (256 of 708) with insulin lispro (odds ratio, 4.2 [95% CI, 3.2-5.5]). The most common adverse events with tirzepatide were mild to moderate gastrointestinal symptoms (nausea: 14%-26%; diarrhea: 11%-15%; vomiting: 5%-13%). Hypoglycemia event rates (blood glucose level &amp;lt;54 mg/dL or severe hypoglycemia) were 0.4 events per patient-year with tirzepatide (pooled) and 4.4 events per patient-year with insulin lispro. Conclusions and Relevance In people with inadequately controlled type 2 diabetes treated with basal insulin, weekly tirzepatide compared with prandial insulin as an additional treatment with insulin glargine demonstrated reductions in HbA 1c and body weight with less hypoglycemia. Trial Registration ClinicalTrials.gov Identifier: NCT04537923" @default.
• W4387296976 created "2023-10-04" @default.
• W4387296976 creator A5008904789 @default.
• W4387296976 creator A5016228682 @default.
• W4387296976 creator A5020174004 @default.
• W4387296976 creator A5045489578 @default.
• W4387296976 creator A5068778743 @default.
• W4387296976 creator A5072715491 @default.
• W4387296976 creator A5086072427 @default.
• W4387296976 creator A5086878406 @default.
• W4387296976 date "2023-10-03" @default.
• W4387296976 modified "2023-10-16" @default.
• W4387296976 title "Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes" @default.
• W4387296976 cites W2053670472 @default.
• W4387296976 cites W2133222023 @default.
• W4387296976 cites W2695892839 @default.
• W4387296976 cites W2770623194 @default.
• W4387296976 cites W2894901807 @default.
• W4387296976 cites W3177122952 @default.
• W4387296976 cites W3177393241 @default.
• W4387296976 cites W3191712049 @default.
• W4387296976 cites W3205201678 @default.
• W4387296976 cites W4210940103 @default.
• W4387296976 cites W4224295659 @default.
• W4387296976 cites W4234995814 @default.
• W4387296976 cites W4241484724 @default.
• W4387296976 cites W4252744551 @default.
• W4387296976 cites W4280597148 @default.
• W4387296976 cites W4289516431 @default.
• W4387296976 cites W4311263987 @default.
• W4387296976 doi "https://doi.org/10.1001/jama.2023.20294" @default.
• W4387296976 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37786396" @default.
• W4387296976 hasPublicationYear "2023" @default.
• W4387296976 type Work @default.
• W4387296976 citedByCount "0" @default.
• W4387296976 crossrefType "journal-article" @default.
• W4387296976 hasAuthorship W4387296976A5008904789 @default.
• W4387296976 hasAuthorship W4387296976A5016228682 @default.
• W4387296976 hasAuthorship W4387296976A5020174004 @default.
• W4387296976 hasAuthorship W4387296976A5045489578 @default.
• W4387296976 hasAuthorship W4387296976A5068778743 @default.
• W4387296976 hasAuthorship W4387296976A5072715491 @default.
• W4387296976 hasAuthorship W4387296976A5086072427 @default.
• W4387296976 hasAuthorship W4387296976A5086878406 @default.
• W4387296976 hasBestOaLocation W43872969761 @default.
• W4387296976 hasConcept C126322002 @default.
• W4387296976 hasConcept C134018914 @default.
• W4387296976 hasConcept C2776486108 @default.
• W4387296976 hasConcept C2777180221 @default.
• W4387296976 hasConcept C2779306644 @default.
• W4387296976 hasConcept C2779920387 @default.
• W4387296976 hasConcept C2780473172 @default.
• W4387296976 hasConcept C2780668416 @default.
• W4387296976 hasConcept C555293320 @default.
• W4387296976 hasConcept C71924100 @default.
• W4387296976 hasConcept C72563966 @default.
• W4387296976 hasConceptScore W4387296976C126322002 @default.
• W4387296976 hasConceptScore W4387296976C134018914 @default.
• W4387296976 hasConceptScore W4387296976C2776486108 @default.
• W4387296976 hasConceptScore W4387296976C2777180221 @default.
• W4387296976 hasConceptScore W4387296976C2779306644 @default.
• W4387296976 hasConceptScore W4387296976C2779920387 @default.
• W4387296976 hasConceptScore W4387296976C2780473172 @default.
• W4387296976 hasConceptScore W4387296976C2780668416 @default.
• W4387296976 hasConceptScore W4387296976C555293320 @default.
• W4387296976 hasConceptScore W4387296976C71924100 @default.
• W4387296976 hasConceptScore W4387296976C72563966 @default.
• W4387296976 hasLocation W43872969761 @default.
• W4387296976 hasLocation W43872969762 @default.
• W4387296976 hasOpenAccess W4387296976 @default.
• W4387296976 hasPrimaryLocation W43872969761 @default.
• W4387296976 hasRelatedWork W1966917180 @default.
• W4387296976 hasRelatedWork W2032866756 @default.
• W4387296976 hasRelatedWork W2131954113 @default.
• W4387296976 hasRelatedWork W2154875560 @default.
• W4387296976 hasRelatedWork W2203412363 @default.
• W4387296976 hasRelatedWork W2324216968 @default.
• W4387296976 hasRelatedWork W2404478897 @default.
• W4387296976 hasRelatedWork W3028798600 @default.
• W4387296976 hasRelatedWork W3141865038 @default.
• W4387296976 hasRelatedWork W2261344402 @default.
• W4387296976 isParatext "false" @default.
• W4387296976 isRetracted "false" @default.
• W4387296976 workType "article" @default.